代谢

CAS号：1186486-62-3

品名：Evacetrapib;反式-4-[[(5S)-5-[[[3,5-双(三氟甲基)苯基]甲基](2-甲基-2H-四氮唑-5-基)氨基]-2,3,4,5-四氢-7,9-二甲基-1H-1-苯并氮杂卓-1-基]甲基]环己烷羧酸Evacetrapib

中文别名：反式-4-[[(5S)-5-[[[3,5-双(三氟甲基)苯基]甲基](2-甲基-2H-四氮唑-5-基)氨基]-2,3,4,5-四氢-7,9-二甲基-1H-1-苯并氮杂卓-1-基]甲基]环己烷羧酸;

英文别名：LY2484595;trans-4-[[(5S)-5-[[[3,5-Bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]cyclohexanecarboxylicacid;4-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]cyclohexane-1-carboxylicacid;

分子式：C31H36F6N6O2

分子量：638.647

精确质量：638.28

Psa：87.38

UNII号：51XWV9K850

密度：1.40

简介：EvacetrapibwasadrugunderdevelopmentbyEliLilly&Company(investigationalnameLY2484595)thatinhibitscholesterylestertransferprotein(CETP),whichtransfersandtherebyincreaseshigh-densitylipoproteinandlowerslow-densitylipoprotein(CETPinhibitor].Itisthoughtthatmodifyinglipoproteinlevelsmodifiestheriskofcardiovasculardisease.ThefirstCETPinhibitor,torcetrapib,wasunsuccessfulbecauseitincreasedlevelsofthehormonealdosteroneandincreasedbloodpressure,whichledtoexcesscardiaceventswhenitwasstudied.Evacetrapibdoesnothavethesameeffect.WhenstudiedinasmallclinicaltrialinpeoplewithelevatedLDLandlowHDL,significantimprovementswerenotedintheirlipidprofile.